Nephrology
Review | Long-term medical outcomes of living kidney donors.
27 Nov, 2022 | 22:04h | UTCLong-term Medical Outcomes of Living Kidney Donors – Mayo Clinic Proceedings
2ry analysis of a RCT | Decongestion with acetazolamide in acute heart failure across the spectrum of left ventricular EF.
25 Nov, 2022 | 12:45h | UTCOriginal Study: RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
Commentary on Twitter
#OriginalResearch simpub #AHA2022 #CIRCAHA22: Acetazolamide added to loop diuretics ⬆️ likelihood of successful decongestion similarily in patients with HFrEF, HFmrEF and HFpEF. Data from the #ADVOR trial. @PieterMartensMD @WilfriedMullens #AHAJournals https://t.co/MkISN2H1vA pic.twitter.com/qFjCKdRaF6
— Circulation (@CircAHA) November 6, 2022
KDIGO 2022 Guideline for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
23 Nov, 2022 | 14:11h | UTCExecutive Summary: KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease – Kidney International
M-A | Cardiac and kidney adverse effects of HIF Prolyl-Hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis.
22 Nov, 2022 | 13:22h | UTC
Cluster RCT | A personalized cooler dialysate provides no benefit for patients receiving maintenance hemodialysis.
21 Nov, 2022 | 14:38h | UTCPersonalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial – The Lancet (link to abstract – $ for full-text)
Commentary: Clinical trial examines optimal dialysis temperature – University of Western Ontario
Commentary on Twitter (thread – click for more)
Over 2 million people worldwide with #kidneyfailure rely on maintenance #dialysis treatments.
Trial, MyTEMP, assesses the effects of cooler dialysate compared with standard temperature in individuals receiving outpatient maintenance dialysis.🧵 pic.twitter.com/M9JscDqM2v
— The Lancet (@TheLancet) November 17, 2022
M-A | Cardiac and kidney adverse effects of HIF Prolyl-Hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis.
21 Nov, 2022 | 14:03h | UTC
ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.
18 Nov, 2022 | 13:23h | UTC
Retrospective Cohort Study | Risk of CKD following detection of microscopic hematuria.
18 Nov, 2022 | 13:11h | UTCNews Release: Persistent hematuria associated with strong risks of chronic kidney disease – National Kidney Foundation
Mild-to-moderate kidney dysfunction and cardiovascular disease: observational and mendelian randomization analyses.
17 Nov, 2022 | 12:18h | UTC
Commentary on Twitter
https://twitter.com/CircAHA/status/1587897418989080577
M-A | Comparative accuracy of biomarkers for predicting hospital-acquired acute kidney injury.
17 Nov, 2022 | 12:09h | UTC
M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.
11 Nov, 2022 | 14:04h | UTCCommentaries:
Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News
EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD
Commentary on Twitter
Our SGLT2 Trialists Consortium meta-analysis *the largest ever* in @TheLancet https://t.co/YlWkRQTDAW
Definitive evidence that SGLT2i ⬇️:
– Kidney failure
– AKI
– CV death
– All-cause deathRegardless of diabetes
Led by @NatalieStaplin @RichardHaynes3 @willkidney #AHA22 pic.twitter.com/uAX15mD9XY
— Brendon Neuen (@brendonneuen) November 6, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
RCT | Dual endothelin antagonist Aprocitentan is effective for resistant hypertension.
11 Nov, 2022 | 13:59h | UTCDual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION – TCTMD
Phase 2RCT | Baxdrostat reduces BP in patients with treatment-resistant hypertension.
11 Nov, 2022 | 13:57h | UTCPhase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study – TCTMD
New Drug Helps Tame Uncontrolled High Blood Pressure – HealthDay
RCT | A small study tested Apixaban’s efficacy and safety versus a Vitamin K-antagonist in patients on chronic hemodialysis.
11 Nov, 2022 | 13:52h | UTCRelated Study: Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial – Circulation
Scoop thrombectomy | Single-center results of a declotting technique for thrombosed autologous arteriovenous fistula.
9 Nov, 2022 | 12:20h | UTC
M-A | Strategies for post–cardiac surgery acute kidney injury prevention.
9 Nov, 2022 | 12:19h | UTC
RCT | Efficacy of a targeted-release formulation of budesonide for treating primary immunoglobulin A nephropathy.
8 Nov, 2022 | 12:14h | UTCCommentary: Oral Steroid Safely Treats IgA Nephropathy: Trial Published – Medscape (free registration required)
Commentary on Twitter (thread – click for more)
https://twitter.com/hswapnil/status/1582685958881021952
SR | Pregnancy after living kidney donation.
8 Nov, 2022 | 11:56h | UTCVideo: Pregnancy after living kidney donation, a review of the available evidence and current guidance
Review | Continuous kidney replacement therapy.
8 Nov, 2022 | 11:51h | UTCContinuous KRT: A Contemporary Review – Clinical Journal of the American Society of Nephrology
Review | Radiographic contrast media and the kidney.
8 Nov, 2022 | 11:49h | UTCRadiographic Contrast Media and the Kidney – Clinical Journal of the American Society of Nephrology
RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.
7 Nov, 2022 | 12:56h | UTCEmpagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News
Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
Commentary on Twitter
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1
— NEJM (@NEJM) November 4, 2022
Cohort Study | Preoperative hemodialysis timing and postoperative mortality in patients with end-stage kidney disease.
7 Nov, 2022 | 12:46h | UTCAssociation Between Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease – JAMA (free for a limited period)
Editorial: Optimal Timing of Hemodialysis Before Surgery – JAMA (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
1/
In @JAMA_current, we asked: Is the timing of hemodialysis before surgery associated with postoperative mortality?The answer: YES
Here’s what we found:https://t.co/ZQl0SHZpAn
— Vikram Fielding-Singh, MD, JD (@vikramfs) November 3, 2022
RCT | Discontinuing RAS inhibitors in patients with advanced CKD did not result in a slower decline in eGFR.
4 Nov, 2022 | 13:55h | UTCRenin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long-term rate of decline in the eGFR. #KidneyWk https://t.co/81EIwG5FQ0 pic.twitter.com/nHNmzlPbHV
— NEJM (@NEJM) November 3, 2022
Consensus Paper | Atypical hemolytic uremic syndrome.
4 Nov, 2022 | 13:40h | UTC
Brief Review | The prediction of fluid responsiveness.
4 Nov, 2022 | 13:39h | UTCThe prediction of fluid responsiveness – Intensive Care Medicine
Commentary on Twitter
Predicting fluid responsiveness in #ICU to avoid administration to patients who do not need & give when needed, allowing for truly personalized treatment
💧fluids could be harmful
💧fluids could be inconstantly effective#FOAMcc free to read on @yourICM
🖇️ https://t.co/os6seDVna2 pic.twitter.com/wy2wDVzfEA— Intensive Care Medicine (@yourICM) November 3, 2022